TRCT
HLVX

Tower Research Capital (TRC)’s HilleVax HLVX Stock Holding History

Tower Research Capital (TRC)’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,516
Closed -$9.45K – 5387
2025
Q1 		$9.45K Buy
6,516
+174
+3% +$322 ﹤0.01% 3776
2024
Q4 		$13.1K Buy
6,342
+650
+11% +$1.22K ﹤0.01% 3556
2024
Q3 		$10K Buy
5,692
+547
+11% +$1.4K ﹤0.01% 3813
2024
Q2 		$74.4K Buy
5,145
+4,600
+844% +$63.2K ﹤0.01% 2800
2024
Q1 		$9.06K Sell
545
-1,911
-78% -$30.6K ﹤0.01% 3906
2023
Q4 		$39.4K Sell
2,456
-82
-3% -$1.09K ﹤0.01% 3280
2023
Q3 		$34.1K Buy
2,538
+150
+6% +$2.11K ﹤0.01% 2910
2023
Q2 		$41K Sell
2,388
-199
-8% -$3.08K ﹤0.01% 2752
2023
Q1 		$43K Buy
2,587
+943
+57% +$15.1K ﹤0.01% 2636
2022
Q4 		$28K Buy
1,644
+1,045
+174% +$18.9K ﹤0.01% 2809
2022
Q3 		$10K Sell
599
-1,773
-75% -$25.8K ﹤0.01% 4537
2022
Q2 		$26K Buy
+2,372
New +$28.2K ﹤0.01% 3511

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Tower Research Capital (TRC)'s HLVX Position: Q2 2025 in Review

Tower Research Capital (TRC) sold out of HilleVax (HLVX) in Q2 2025, closing a stake of 6,516 shares — an estimated $9.45K sold.

Tower Research Capital (TRC) first reported a position in HLVX in Q2 2022 and held it in 12 quarters. The position peaked at $74.4K in Q2 2024. 74 funds tracked by Wall St. Rank hold HLVX as of Q2 2025.

  • Tower Research Capital (TRC) reported no remaining HilleVax position as of Q2 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 6,516 HilleVax shares in Q2 2025, an estimated $9.45K.
  • Tower Research Capital (TRC) first reported a position in HilleVax in Q2 2022 and held it in 12 quarters.
  • Tower Research Capital (TRC)'s HilleVax position peaked at $74.4K in Q2 2024.
  • 74 funds tracked by Wall St. Rank held HilleVax as of Q2 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.